Related Experiment Video
Updated: Feb 5, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network
Xinghua Xu1, Sumin Chi2, Qun Wang1
1Department of Neurosurgery, Chinese PLA General Hospital, 28th Fuxing Road, Beijing 100853, China; National Clinical Research Center for Aging and Medicine, Chinese PLA General Hospital, Beijing, China.
Background:
Several monoclonal antibodies have been licensed for relapsing remitting multiple sclerosis (RRMS). It is still unclear which treatment regimen should be recommended due to the lack of head-to-head randomized controlled trials (RCTs). This study aims to investigate the relative efficacy and safety of existing monoclonal antibody therapies in treating RRMS.
Methods:
We searched PubMed, Embase, and the Cochrane Library for RCTs of monoclonal antibodies for treatment of RRMS. We performed a network meta-analysis to identify evidence comparing monoclonal antibodies with one another, interferon beta-1a (INFβ-1a), or placebo in adult patients with RRMS. The primary efficacy outcome was annualized relapse rate and the primary safety outcome was incidence rate of serious adverse events.
Results:
A total of 14 eligible studies containing 9412 patients treated with 7 regimens were analyzed. INFβ-1a was the most common comparison treatment and showed an annualized relapse rate of 45.3%. All monoclonal antibody regimens, including natalizumab, natalizumab plus INFβ-1a, alemtuzumab, daclizumab, and ocrelizumab, were associated with significant reduction in annualized relapse rate and similar risks of serious adverse events. Cluster analysis showed that natalizumab plus INFβ-1a and alemtuzumab performed best in terms of high efficacy and safety. Natalizumab and daclizumab were characterized by high efficacy but relatively high risk of serious adverse events. Ocrelizumab was differentiated by high safety but relatively poor efficacy.
Conclusion:
This network meta-analysis provided a comprehensive summary of efficacy and safety of monoclonal antibodies for RRMS, which might provide a reference for treatment. More direct comparison studies are warranted.
Insights
Monoclonal antibodies significantly reduce relapses in relapsing remitting multiple sclerosis (RRMS). Natalizumab plus interferon beta-1a and alemtuzumab offer the best balance of efficacy and safety for RRMS treatment.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Several monoclonal antibodies are approved for relapsing remitting multiple sclerosis (RRMS).
- Lack of head-to-head trials makes treatment selection challenging.
- This study compares the efficacy and safety of available monoclonal antibody therapies for RRMS.
Purpose of the Study:
- To conduct a network meta-analysis comparing monoclonal antibodies for RRMS.
- To evaluate relative efficacy and safety against placebo and interferon beta-1a.
- To provide evidence-based guidance for RRMS treatment selection.
Main Methods:
- Systematic search of PubMed, Embase, and Cochrane Library for RCTs.
- Network meta-analysis of 14 studies involving 9412 patients.
- Primary outcomes: annualized relapse rate and serious adverse events.
Main Results:
- All monoclonal antibodies reduced annualized relapse rate compared to interferon beta-1a (45.3% ARR).
- Natalizumab plus INFβ-1a and alemtuzumab showed high efficacy and safety.
- Natalizumab and daclizumab had high efficacy but higher adverse event risks; ocrelizumab had high safety but lower efficacy.
Conclusions:
- Network meta-analysis offers a comprehensive RRMS treatment comparison.
- Natalizumab plus INFβ-1a and alemtuzumab are promising options.
- Further direct comparison studies are needed for definitive guidance.
Related Concept Videos
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Survey Safety
Self-Efficacy
Directing Effect of Substituents: meta-Directing Groups
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
Household Wiring And Electrical Safety

